Legal & General Group
OVID icon

Legal & General Group’s Ovid Therapeutics OVID Stock Holding History

Legal & General Group’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,579
Closed -$2.05K – 3504
2025
Q1 		$2.05K Hold
6,579
– – ﹤0.01% 3352
2024
Q4 		$6.14K Hold
6,579
– – ﹤0.01% 3325
2024
Q3 		$7.76K Hold
6,579
– – ﹤0.01% 3316
2024
Q2 		$5.06K Buy
6,579
+1,378
+26% +$3.83K ﹤0.01% 3377
2024
Q1 		$15.9K Hold
5,201
– – ﹤0.01% 3060
2023
Q4 		$16.7K Buy
5,201
+588
+13% +$2.01K ﹤0.01% 3102
2023
Q3 		$17.7K Sell
4,613
-1,150
-20% -$4.13K ﹤0.01% 3085
2023
Q2 		$18.9K Buy
+5,763
New +$19.6K ﹤0.01% 3130
2021
Q2 		– Sell
-5,199
Closed -$21K – 3605
2021
Q1 		$21K Sell
5,199
-21,322
-80% -$70.8K ﹤0.01% 3116
2020
Q4 		$61K Buy
26,521
+21,322
+410% +$99.4K ﹤0.01% 2746
2020
Q3 		$30K Sell
5,199
-1,863
-26% -$12.5K ﹤0.01% 2851
2020
Q2 		$52K Buy
+7,062
New +$33K ﹤0.01% 2718
2019
Q3 		– Sell
-2,145
Closed -$4K – 3398
2019
Q2 		$4K Hold
2,145
– – ﹤0.01% 3459
2019
Q1 		$4K Hold
2,145
– – ﹤0.01% 3321
2018
Q4 		$5K Hold
2,145
– – ﹤0.01% 3336
2018
Q3 		$12K Hold
2,145
– – ﹤0.01% 3302
2018
Q2 		$17K Hold
2,145
– – ﹤0.01% 3227
2018
Q1 		$15K Buy
2,145
+1,047
+95% +$8.47K ﹤0.01% 3162
2017
Q4 		$11K Hold
1,098
– – ﹤0.01% 3227
2017
Q3 		$10K Hold
1,098
– – ﹤0.01% 3278
2017
Q2 		$11K Buy
+1,098
New +$14.3K ﹤0.01% 3307

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Legal & General Group's OVID Position: Q2 2025 in Review

Legal & General Group sold out of Ovid Therapeutics (OVID) in Q2 2025, closing a stake of 6,579 shares — an estimated $2.05K sold.

Legal & General Group first reported a position in OVID in Q2 2017 and held it in 21 quarters. The position peaked at $61K in Q4 2020. 71 funds tracked by Wall St. Rank hold OVID as of Q2 2025.

  • Legal & General Group reported no remaining Ovid Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 6,579 Ovid Therapeutics shares in Q2 2025, an estimated $2.05K.
  • Legal & General Group first reported a position in Ovid Therapeutics in Q2 2017 and held it in 21 quarters.
  • Legal & General Group's Ovid Therapeutics position peaked at $61K in Q4 2020.
  • 71 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.